Claim Details
View detailed information about this claim and its related sources.
Claim Information
Complete details about this extracted claim.
- Claim Text
-
We now have amyloid therapeutics which are able to slow the progression of the disease and future therapies now have the potential to add on to those and have an even bigger impact.
- Simplified Text
-
Amyloid therapeutics slow disease progression future therapies may have bigger impact
- Confidence Score
- 0.500
- Claim Maker
- R. Hargreaves
- Context Type
- Website Article
- Context Details
-
{ "date": null } - Subject Tags
- UUID
- 9fc8a1b0-f54e-4b57-8ca1-84ce03733403
- Vector Index
- ✗ No vector
- Created
- September 2, 2025 at 7:15 PM (1 week ago)
- Last Updated
- September 2, 2025 at 7:15 PM (1 week ago)
Original Sources for this Claim (1)
All source submissions that originally contained this claim.
37
claims
🔥
1 week ago
https://www.bms.com/life-and-science/science/renaissance-neuroscience-research-development.html?cid=d_3267515&dclid=CN-sjNPAsI8DFazArQAd_vguSA&gad_source=7
Bristol Myers Squibb is accelerating neuroscience R&D using breakthroughs in human biology, biomarkers, and computational science to improve outcomes for patients with neurological conditions. The company is exploring new approaches to slow disease progression and alleviate symptoms.
Similar Claims (0)
Other claims identified as semantically similar to this one.
No similar claims found
This claim appears to be unique in the system.